Total Funding
65
56
Total FundingVenture - Series Unknown raised
Growth Score
-3 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
40139
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood.
- Alex Wieseler: COO
- Sinead Miller: CEO
About the Company
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EX
is taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths.
Women Founded
Women Led
